Yarrow
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
About Yarrow
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Company Facts
- Headquarters
- New York
- Founded
- 2021
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Total Funding
- $200,000,000
- Last Funding Type
- series_unknown
- Last Funding Date
- 2025-12-17
- Website
- https://www.yarrowbioscience.com
Industries & Categories
Business Intelligence, Health Care, Medical
Canonical: https://fsome.com/organization/yarrow-122330 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.